Bristol-Myers Squibb (BMY) said late Thursday that the US Food and Drug Administration granted accelerated approval to Zenbexus in combination with daratumumab and hyaluronidase-fihj and dexamethasone to treat multiple myeloma.
https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-gets-fda-215632694.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.